BostonGene and the SWOG Cancer Research Network initiated the S2409 PRISM Phase 2 clinical trial for extensive-stage small cell lung cancer (ES-SCLC). Utilizing BostonGene's machine learning-driven multiomic platform, the trial aims to stratify up to 900 patients by molecular subtypes and SLFN11 status to evaluate maintenance treatments. The study incorporates novel agents such as AstraZeneca’s PARP inhibitor saruparib and immunotherapies, seeking to refine biomarker-directed therapy in ES-SCLC. The trial leverages collaboration with the National Cancer Institute's trial network and builds upon prior subtype discovery work.